A 32-year-old woman from Mumbai attends the family planning clinic requesting a change in her contraceptive method. She has been using a combined oral contraceptive (COC) containing 30 μg ethinyl estradiol and norgestimate for 5 years without complications. However, she now reports breakthrough bleeding on days 15–18 of the cycle and occasional spotting. Her blood pressure is 120/78 mmHg, BMI 26 kg/m², and pelvic examination is normal. What is the most likely cause of her breakthrough bleeding, and what is the most appropriate management?

Explanation

## Clinical Context Breakthrough bleeding (BTB) in a woman on a stable COC regimen is a common side effect that requires systematic evaluation. The timing (mid-cycle, days 15–18) and pattern (spotting) are key diagnostic clues. ## Pathophysiology of Breakthrough Bleeding **Key Point:** BTB on COCs is caused by **inadequate endometrial support**, which results from either: 1. **Insufficient estrogen** → endometrial atrophy 2. **Insufficient progestin** → inadequate endometrial stabilization **High-Yield:** The **timing and pattern** of BTB help differentiate the cause: | Timing | Pattern | Likely Cause | Management | | --- | --- | --- | --- | | Days 8–13 (follicular phase) | Spotting | **Inadequate estrogen** | ↑ Estrogen dose (e.g., 35 → 50 μg EE) | | Days 15–21 (luteal phase) | Spotting or light bleeding | **Inadequate progestin** | ↑ Progestin potency or dose | | Random or continuous | Heavy bleeding | Structural pathology or poor compliance | Investigate; counsel on adherence | **Clinical Pearl:** In this case, BTB occurs on **days 15–18 (luteal phase)**, suggesting **inadequate progestin effect** rather than estrogen deficiency. The endometrium is initially stabilized by estrogen in the follicular phase but destabilizes in the luteal phase when progestin support is insufficient. ## Why Inadequate Progestin is the Answer **Mechanism:** - Progestins stabilize the endometrium by promoting secretory changes and reducing endometrial vascularity. - Insufficient progestin → endometrial fragility → breakthrough bleeding in the luteal phase (when progesterone naturally falls). - The current dose (norgestimate in a 30 μg EE pill) may be inadequate for this patient's endometrial threshold. **Management Options:** 1. **Switch to a COC with higher progestin potency** (e.g., norgestrel, levonorgestrel, or desogestrel at higher doses) 2. **Increase the progestin dose** while keeping estrogen constant 3. **Extend the pill-free interval** (e.g., 21/7 to 24/4 regimen) — allows more endometrial proliferation 4. **Consider continuous or extended-cycle COCs** (e.g., Seasonale: 84 active + 7 placebo) ## Why Other Options Are Incorrect **Option 0 (↑ Estrogen to 50 μg):** - Estrogen-deficient BTB typically occurs in the **follicular phase (days 8–13)**, not the luteal phase. - Increasing estrogen to 50 μg is outdated practice and increases thrombotic risk unnecessarily. - Modern COCs use 20–35 μg EE; 50 μg formulations are rarely used. **Option 2 (Cervicitis/endometritis):** - No systemic signs (fever, pelvic pain, vaginal discharge) are mentioned. - Pelvic examination is normal. - Cervicitis would cause abnormal vaginal discharge and cervical tenderness, not isolated BTB. **Option 3 (Poor compliance):** - The patient has used the same COC for 5 years without complications, suggesting good adherence. - Sudden onset of BTB after years of stable use indicates a change in pharmacodynamics, not compliance. - Poor compliance typically causes **unscheduled heavy bleeding** (missed pills → hormone withdrawal), not mid-cycle spotting. ## Mnemonic for BTB Causes **"STEP" approach:** - **S**tructure (polyps, fibroids, cancer) → pelvic ultrasound - **T**hrombin/coagulation disorders → PT/INR, CBC - **E**ndocrine (thyroid, PCOS) → TSH, LH/FSH - **P**ill factors (inadequate hormone dose) → adjust COC formulation [cite:KD Tripathi 8e Ch 65; Harrison 21e Ch 336]